<DOC>
	<DOCNO>NCT01743677</DOCNO>
	<brief_summary>ICH E14 recommend thorough QT/QTc ( TQT ) study perform determine whether intensive monitoring QT interval target patient population require later stage development . The current study design ascertain whether CP-690,550 associate QTc prolongation .</brief_summary>
	<brief_title>CP-690,550 Thorough QTc Study</brief_title>
	<detailed_description>The current study design ascertain whether CP-690,550 associate QTc prolongation</detailed_description>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . 12lead ECG demonstrate QTc &gt; 450 msec clinically significant abnormality Screening . History risk factor QT prolongation torsades de pointes . Pregnant nursing woman ; woman childbearing potential unwilling unable use acceptable method nonhormonal contraception least 14 day prior first dose completion followup . Use prescription nonprescription drug , vitamin dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose trial medication . Any clinically significant infection within past 3 month evidence infection past 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>TQT study</keyword>
	<keyword>CP-690,550</keyword>
</DOC>